Drug class
Second-line antitubercular; para-aminobenzoic acid (PABA) analogue and antifolate
Mechanism of action
A prodrug incorporated by mycobacterial folate-pathway enzymes to form a hydroxylated dihydrofolate antimetabolite that inhibits dihydrofolate reductase. It also interferes with folate and mycobactin-related pathways and has bacteriostatic activity against Mycobacterium tuberculosis.
General use cases
- Companion drug in selected multidrug regimens for drug-resistant tuberculosis when recommended by current WHO or national treatment guidance.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
